MNKT.Q Stock Overview Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Mallinckrodt plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Mallinckrodt Historical stock prices Current Share Price US$0.12 52 Week High US$12.15 52 Week Low US$0.026 Beta 0 1 Month Change 220.00% 3 Month Change -79.26% 1 Year Change -98.99% 3 Year Change n/a 5 Year Change n/a Change since IPO -99.35%
Recent News & Updates
CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) completed the acquisition of Therakos (France) Sas from Mallinckrodt plc. Dec 02
Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting Nov 19
Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024 Oct 27
Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024 Oct 24
Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector Sep 17 CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million. See more updates
CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) completed the acquisition of Therakos (France) Sas from Mallinckrodt plc. Dec 02
Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting Nov 19
Mallinckrodt plc Presents Data on Terlipressin (Terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) At Kidney Week 2024 Oct 27
Mallinckrodt plc to Report Q3, 2024 Results on Nov 05, 2024 Oct 24
Mallinckrodt plc Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use®? Certification of Acthar®? Gel (repository Corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector Sep 17 CVC Capital Partners Fund IX managed by CVC Capital Partners plc (ENXTAM:CVC) entered into a definitive agreement to acquire Therakos business of Mallinckrodt from Mallinckrodt plc for approximately $925 million.
Mallinckrodt plc to Report Q2, 2024 Results on Aug 06, 2024 Aug 01
Mallinckrodt plc Presents Data on Terlipressin for Injection in Patients with Hepatorenal Syndrome at the 2024 European Association for the Study of the Liver (EASL) Congress Jun 06
Mallinckrodt plc Reaffirms Financial Guidance for the Full Year of 2024 May 10
Mallinckrodt plc, Annual General Meeting, May 09, 2024 Apr 16
Mallinckrodt plc Provides Earnings Guidance for the Year 2024 Mar 27
Mallinckrodt Appoints Paul O'neill as Executive Vice President, Quality & Operations, Specialty Brands Mar 05
Mallinckrodt plc Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® Mini-Cylinder Dec 08 Mallinckrodt plc to Present Breadth of Data on Terlivaz (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome At the American Association for the Study of Liver Diseases (Aasld) 2023 Liver Meeting
Mallinckrodt plc Revises Earnings Guidance for the Full-Year of 2023 Nov 08
Mallinckrodt Presents Latest Health Economics Data on Acthar Gel (Repository Corticotropin Injection) At the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 Oct 28
Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar Gel (Repository Corticotropin Injection) Oct 11 Mallinckrodt Reportedly Considers Sale of Opioid Business Sep 20
Mallinckrodt plc Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD) Sep 01 Mallinckrodt plc(OTCPK:MNKT.Q) dropped from S&P TMI Index Aug 31
NYSE American to Commence Delisting Proceedings Against Mallinckrodt Mallinckrodt plc Filed for Bankruptcy Aug 28
Mallinckrodt plc is Heading Towards Bankruptcy Aug 24
Mallinckrodt plc Contemplates Bankruptcy Aug 17
Mallinckrodt plc Reaffirms Sales Guidance for the Full-Year 2023 Aug 10
Pomerantz LLP Announces That a Class Action Lawsuit Has Been Filed Against Mallinckrodt plc Jul 10 Alta Fundamental Requests Mallinckrodt to Convene an Extraordinary General Meeting
Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome Jun 17
Mallinckrodt Announces Publication of Real-World Data on the Use of Extracorporeal Photopheresis (ECP) in Heart Transplant Patients Jun 13
Mallinckrodt plc Presents Clinical Data for TERLIVAZ® (terlipressin) for Injection in Adults with Hepatorenal Syndrome (HRS) at the American Transplant Congress (ATC) 2023 Jun 02
Mallinckrodt plc Provides Earnings Guidance for the Year 2023 May 10
Mallinckrodt plc to Report Q4, 2022 Results on Feb 28, 2023 Feb 09
Mallinckrodt plc Presents New TERLIVAZ® for Injection Data on Hepatorenal Syndrome Reversal at the Society of Critical Care Medicine 2023 Critical Care Congress Jan 23
Mallinckrodt plc Announces Appointment of Peter Richardson as Chief Scientific Officer Jan 13
Mallinckrodt plc Provides Financial Guidance for the Full-Year 2022 Nov 09
Mallinckrodt to Present Data on Terlivaz® (Terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (Hrs) At the American Society of Nephrology (Asn) Kidney Week 2022 Scientific Meeting Nov 02
Mallinckrodt plc NEW SHS Deleted from OTC Equity Oct 29
Mallinckrodt plc to Report Q3, 2022 Results on Nov 08, 2022 Oct 19
Mallinckrodt plc Appoints Karen L. Ling as Human Resources and Compensation Committee of the Board Oct 13
Mallinckrodt plc Appoints Susan Silbermann to Its Board of Directors Oct 07
Mallinckrodt plc Announces Submission of 510(k) to the U.S. FDA for Inhaled Nitric Oxide Delivery System Sep 29
Mallinckrodt plc Announces Appointment of Lisa French as Executive Vice President and Chief Commercial Officer, Effective October 1, 2022 Sep 20
Mallinckrodt Receives U.S. FDA Approval for Terlivaz (Terlipressin) for Injection for the Treatment of Hepatorenal Syndrome (HRS) Sep 15
Mallinckrodt plc, Annual General Meeting, Sep 29, 2022 Aug 19 Mallinckrodt plc Provides Update on Executive Committee
Mallinckrodt plc Provides Revenue Guidance for the Full Year of 2022 Aug 12 Shareholder Returns MNKT.Q US Pharmaceuticals US Market 7D 33.3% 1.6% -2.2% 1Y -99.0% 9.7% 23.9%
See full shareholder returns
Return vs Market: MNKT.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility Is MNKT.Q's price volatile compared to industry and market? MNKT.Q volatility MNKT.Q Average Weekly Movement 45.0% Pharmaceuticals Industry Average Movement 10.4% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: MNKT.Q's share price has been volatile over the past 3 months.
Volatility Over Time: MNKT.Q's weekly volatility has decreased from 77% to 45% over the past year, but is still higher than 75% of US stocks.
About the Company Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, hepatology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products.
Show more Mallinckrodt plc Fundamentals Summary How do Mallinckrodt's earnings and revenue compare to its market cap? MNKT.Q fundamental statistics Market cap US$936.02k Earnings (TTM ) -US$2.97b Revenue (TTM ) US$1.89b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MNKT.Q income statement (TTM ) Revenue US$1.89b Cost of Revenue US$1.25b Gross Profit US$640.60m Other Expenses US$3.61b Earnings -US$2.97b
Last Reported Earnings
Sep 29, 2023
Earnings per share (EPS) -222.21 Gross Margin 33.97% Net Profit Margin -157.55% Debt/Equity Ratio -34.4%
How did MNKT.Q perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/11/14 21:57 End of Day Share Price 2023/11/14 00:00 Earnings 2023/09/29 Annual Earnings 2022/12/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Mallinckrodt plc is covered by 29 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Argus Research Company Douglas Tsao Barclays Patrick Trucchio Berenberg
Show 26 more analysts 